| Powder: -20°C for 3 years | In solvent: -80°C for 2 years
RSL3 是一种不依赖 VDAC 的铁死亡激活剂,对携带致癌 RAS 的肿瘤细胞具有选择性。 它是谷胱甘肽过氧化物酶 4 的抑制剂,可抑制阻断 GSH 合成的半胱氨酸/谷氨酸氨基酸转运系统 xc-,IC50为100 nM。
产品描述 | RSL3 is a VDAC-independent ferroptosis activator with selectivity for tumor cells bearing oncogenic RAS. RSL3 is the inhibitor of the glutathione peroxidase 4, which can inhibit the cysteine/glutamate amino acid transporter system xc- that blocks GSH synthesis (IC50: 100 nM). | ||||||||||||||||
靶点活性 | GSH:100 nM | ||||||||||||||||
体外活性 |
Ferroptosis-inducing compounds inactivate GPX4 by direct binding or by depleting glutathione.After binding to GPX4, RSL3 inactivates GPX4 to induce ROS production from lipid peroxidation. RSL3's ability to induce synthetic lethality with oncogenic RAS is rapid and quite potent. This compound inhibits the growth of BJ-TERT/LT/ST/RASV12 and DRD cells as low as 10 ng/mland started to kill sensitive cells as early as 8 hr after treatment[1][2].
|
||||||||||||||||
体内活性 |
Prostaglandin-endoperoxide synthase (PTGS) is the key enzyme in prostaglandin biosynthesis. There are two isozymes of PTGS: a constitutive PTGS1 and an inducible PTGS2. PTGS2 encoding cyclooxygenase-2 (COX-2) is significantly upregulated after treatment with RSL3 and erastin in mice[1].
|
||||||||||||||||
细胞实验 | TERT/LT/ST/RASV12 cells are seeded in 10 cm dishes and treated with 1 µM staurosporine, 10 µg/ml erastin, 20 µg/ml RSL5, and 1 µg/ml RSL3 for 16 hr. Both dying cells and live cells in each 10 cm dish are harvested and collected in the same 15 ml tubes by centrifuging cell suspension at 1000 rpm for 5 min. (Only for Reference) |
别名 | RSL3 1S, 1S,3R-RSL3 |
化合物与蛋白结合的复合物 |
Crystal structure of human GPX4-U46C in complex with RSL3 |
分子量 | 440.88 |
分子式 | C23H21ClN2O5 |
CAS No. | 1219810-16-8 |
| Powder: -20°C for 3 years | In solvent: -80°C for 2 years
DMSO: 44.1 mg/mL (100 mM)
( < 1 mg/mL refers to the product slightly soluble or insoluble )
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
bottom
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
RSL3 1219810-16-8 Apoptosis Metabolism oxidation-reduction Ferroptosis GPX Glutathione Peroxidase RSL-3 inhibit RSL3 1S (1S,3R)-RSL3 RSL 3 Inhibitor 1S,3R-RSL3 inhibitor